To fulfill Neuright’s Mission, Vision, and Promise, we have created a new theragnostic platform (combining therapy and diagnostic functions) that can provide sensitive diagnosis, neuropathy therapy to promote nerve re-growth, and drug delivery. The diagnostic is our minimum viable product (MVP) and is currently under R&D optimization and preclinical validation. Here is where we are to date, along with some upcoming milestones: > We have received more than $100,000 in non-diluted grant funding to date.This funding has allowed us to take our product from the bench, bring it through customer-discovery market research, and create our company. > Right now we are filing to register our intellectual property and testing our prototype, putting it through preclinical validation. > With $25,000 from the Maine Top Gun program, we are able to put our minimum viable product into clinical trials. > By 2023 we expect our product to be ready to be distributed to thought leaders throughout the nation.